Cipher Research

SpaceX is a generational infrastructure asset with real Starlink economics, launch dominance, and AI/orbital compute optionality, but the $135 IPO price around a $1.75T valuation already prices in multiple future wins. Social, prediction, Binance, and Hyperliquid synthetic markets point to strong first-day demand, while corporate valuation work remains cautious. Treat any allocation as small event exposure, not a clean fundamental bargain.

Nakamoto is a real Bitcoin-native public operating-company experiment with BTC Inc., UTXO and a meaningful Bitcoin treasury, but the equity is not yet investable: large dilution/overhang, related-party governance optics, weak segment economics, BTC volatility, and a near-total stock collapse overwhelm the apparent asset-value discount. Watchlist only until BTC-per-share accretion, custody, issuance discipline, and segment profitability are proven.

Bank Frick is a credible, profitable Liechtenstein bank with a differentiated regulated crypto-banking franchise, MiCAR authorisation, xPULSE payments, custody/staking, and real AUM. The opportunity is worth diligence if a strategic-investor process is accessible, but public data is not enough to underwrite valuation, compliance, client concentration, custody controls, or segment profitability.

Plover Bay is a profitable, founder-controlled HK-listed connectivity platform with real Starlink/Peplink validation, rising recurring revenue, net cash, and a planned North America/NASDAQ spinoff catalyst. The quality is real, but valuation, founder control, Starlink revenue opacity, and spinoff execution risk make it a disciplined buy-on-weakness candidate rather than a blind chase.

RoboStrategy is a scarce public wrapper for private robotics and embodied-AI exposure, but the stock trades at a multi-hundred-percent premium to recently disclosed NAV, the portfolio is mostly Level 3 private securities, and the $2B equity facility creates major dilution/overhang risk. Watchlist only unless price converges toward verified NAV or issuance proves consistently NAV-accretive.

Finder is a real, scaled, founder-led comparison and lead-generation platform with public evidence of roughly $100M+ revenue scale, but audited financials, traffic economics, cap table, partner concentration, and unit economics are not public. Conditional only; do not invest on public data alone.

Nintendo is a cash-rich global entertainment/IP platform with a validated Switch 2 cycle and exceptional first-party IP. Goldman Sachs maintained Buy but cut its target and estimates after the miss, reinforcing that price-hike, cost, guidance and software-attach risks require disciplined accumulation only on weakness.

AI-native mortgage-finance turnaround with real funded-volume recovery and Tinman platform momentum, but FY2025 net loss roughly equaled revenue, leverage/dilution risk remains live, and founder/governance overhang is too material for a buy at current public-market evidence level.

Updated rerun of the April 26 Galaxy Digital report. Score moves to 52/100 from 48/100 because Helios has delivered its first CoreWeave data hall, Q1 filings are now available, liquidity remains strong at $2.6B cash/stablecoins, and the Nasdaq-only listing is cleaner. Still not a chase: Q1 delivered a $216M GAAP loss, negative $188M adjusted EBITDA, high beta, and material Helios execution/concentration risk. Best answer: wait for a pullback toward $24-25 or Q2 Helios proof; buy only a starter if exposure is needed now.

HKEX-filings-based public-market analysis of OSL Group including 2025 annual and interim results. Strong top-line growth, but the stock case weakened after a swing back to loss.

One-page investor memo including 2025 results, updated score, key risks, and price sensitivity for OSL Group.

Global EM co-investment fund with world-class deal flow and 71 unicorns across 50+ countries. Excellent gross returns (2-3.7x MOIC) undermined by 50% carried interest — 2.5x above market — reducing net LP returns to mediocre 6-13% IRR. Invest with conditions for impact-oriented LPs; pass for pure return maximizers.

Preclinical biotech developing Endogenous Repair Modulators (ERM Therapies™) to reverse tissue damage. World-class team (Gorlin: $14.2B Medivation exit; Fleisher: ex-CMS CMO) with novel SRC activation mechanism showing 78% fibrosis reduction in mouse models. Critical risks: foundational scientist Dr. O'Malley died Nov 2025, all data internal/unpublished, no cap table or valuation disclosed, $75M raise is 3-5x above preclinical median.

Humanoid robotics company targeting manufacturing, logistics, and defense. Compelling market opportunity undermined by founder credibility crisis, customer concentration risk, and unproven manufacturing scale.

VC fund-of-funds investing in top-tier U.S. seed-stage managers (Neo, SPC, Spider, Fifty Years) with LP-friendly economics (0.78% mgmt / 10% carry / 8% hurdle). 1.29x gross multiple in <1 year with Groq realized at $20B via Nvidia acquisition. GP has institutional-grade pedigree (Credit Suisse, GCM Grosvenor, CreditEase $1B AUM). First-time independent fund risk mitigated by exceptional manager selection and below-market fee structure.

AI-focused $50M seed fund led by two serial operator-GPs (Berenguer: 6x founder, CoverWallet→Aon, first investor in Flywire $5B IPO; Christanto: 3x founder, Ontruck/Atomico). Strong shared GP portfolio (Stack AI 5x, MITO AI 3.6x, Sully AI 3.5x) with Tier 1 co-investors (Lightspeed, Eclipse, Bessemer). Key concerns: first-time independent fund, CoverWallet exit magnitude unverifiable ($300M claim vs. $28M raised), all returns paper (DPI=0), LifeX→Evident transition unexplained, low 1.3x hurdle rate.